Salute e Benessere

Xiaohongshu and VOGUE Business Redefine Home Aesthetics During Milan Fashion…

Aligning perfectly with Xiaohongshu's human-centric values, consumers are increasingly seeking harmony between their home environments and personal lifestyles. As a lifestyle community beloved by youth, the social media platform excels in understanding people's needs, gaining insights into emerging consumer scenarios and industry trends in China. According to Xiaohongshu Research, as of Q2 2024, with a monthly active user base of 300 million, nearly 65% of whom are passionate about home life…
PR Newswire
30/09/2024

SIFI announces allowance of patent on polihexanide for Europe and commercial…

The Patent grant follows SIFI's findings in the Phase 3 clinical trial, where AKANTIOR® (polihexanide 0.08%) demonstrated an 86% clinical resolution rate in AK, with an average time-to-cure of approximately 4 months. The Patent also covers the novel dosing regimen of 16 drops/day for first 5 days, 8 drops/day for the following 7 days, 6 drops/day for the following 7 days and 4 drops/day until clinical resolution. The proven dosing regimen represents also a major improvement in patients' quality…
PR Newswire
30/09/2024

Orion's near-term climate targets approved by the Science Based Targets…

ORION CORPORATION PRESS RELEASE 30 SEPTEMBER 2024 at 10.00 a.m. EEST Orion's near-term climate targets approved by the Science Based Targets initiative Orion Corporation is proud to announce that the Science Based Targets initiative (SBTi) has validated our near-term science-based targets. This means that our greenhouse gas (GHG) emissions reduction targets align with the latest climate science to limit global warming to 1.5°C above pre-industrial levels. Orion Corporation commitsto...
Nasdaq GlobeNewswire
30/09/2024

Change in number of shares and votes in Immunovia AB (publ)

Karin Almqvist Liwendahl, [email protected] +46 70 911 56 08 Karin Almqvist Liwendahl, [email protected] +46 70 911 56 08 This information is such information that Immunovia AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, on 30 September 2024 at08:30 CET. Immunovia in brief Immunovia...
PR Newswire
30/09/2024

New number of shares and votes in Sobi

Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2023, revenue amounted to SEK 22.1 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn…
PR Newswire
30/09/2024

Photocure Partner Asieris Unveils Cevira (APL-1702) Phase III Subgroup Analysis…

Furthermore, the study results included the pathological regression rate (defined as the proportion of subjects with a pathological regression to CIN1 or normal tissue) at the 6th month across different age subgroups. Both the "≥20 and <30 years" subgroup and the "≥30 and <40 years" subgroup showed an increase of 15% to 20% in the pathological regression rate in the APL-1702 group compared to the placebo control group. No cervical cancer events were reported, suggesting…
PR Newswire
30/09/2024

BioSenic announces that it has started to look for new assets, the securing of…

PRIVILEGED INFORMATION Biosenic and Global Tech Opportunities 15 ("GTO 15") have entered into an amendment to the convertible bonds ("CB") agreement securing a further EUR 1.5 million of the programme, including at least two tranches of EUR 0.2 million net each. François Rieger and Véronique Pomi-Schneiter resign from their positions as CEO, chairman and executive director and non-executive director respectively, to focus on Medsenic. Finsys Management SRL, represented by its…
Nasdaq GlobeNewswire
30/09/2024

kdc/one strengthens its cosmetics packaging capabilities with the acquisition of…

Sandra Wisniewski, Global President Beauty and Personal Care at kdc/one, said: "This strategic acquisition significantly enhances our ability to offer innovative packaging solutions, complementing our comprehensive full-service capabilities that include ideation, design, formulation development, and manufacturing." Sandra Wisniewski, Global President Beauty and Personal Care at kdc/one, said: "This strategic acquisition significantly enhances our ability to offer innovative…
PR Newswire
30/09/2024

HSL CHAIRS : EXPERT REVEALS SITTING IN CORRECT SIZE CHAIR REDUCES BLOOD PRESSURE

The research also highlights that the right fitting chair reduces fidgeting, which contributes towards maintaining a good posture, limiting common aches and pains. The research also highlights that the right fitting chair reduces fidgeting, which contributes towards maintaining a good posture, limiting common aches and pains. Conducted by DrAndrea Utley, from the University's School of Biomedical Sciences, 24 participants, aged between 32 and 72, took part in the study. The...
PR Newswire
30/09/2024

Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results…

Launched Neurosterix with Perceptive Advisors to accelerate the development of M4PAM for schizophreniaIndivior selected GABA B PAM drug candidate for development in substance use disordersAddex selected independent GABAB PAM drug candidate for development in chronic cough Ad Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, September 30, 2024-Addex Therapeutics(SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of...
Nasdaq GlobeNewswire
30/09/2024

BioSenic reports half year 2024 results

REGULATED INFORMATION The interim financial report is prepared in accordance with article 13 of the Royal Decree on the obligations of issuers of financial instruments admitted to trading on a regulated market and can be accessed on the website of Biosenic in the section 'Financial reports'. BioSenic publishes its interim financial report in English. A French translation of the report will also be made available. In the event of differences between the English and the French version of the...
Nasdaq GlobeNewswire
30/09/2024

DREAM Pivotal Study Data Presented at the International Surgical Sleep Society…

DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational UpdateAdditional clinical data on patients suffering from Obstructive Sleep Apnea (OSA) demonstrate a clinically significant 71.0% median reduction in Apnea-Hypopnea index (AHI) while sleeping supine at 12 months compared with baseline.82.0% of patients who completed a polysomnography at 12 months had an AHI below 15, and 67.4% of patients who completed a polysomnography at 12 months had...
Nasdaq GlobeNewswire
27/09/2024

Sectra enterprise imaging in the cloud to foster collaboration across 150 sites…

"I am honored by the trust MSSS Québec has placed in us in helping them enhance patient care across the province. This opportunity represents a significant milestone for Sectra in Canada and highlights our commitment to delivering innovative healthcare solutions. As we enter this exciting phase, we are excited about the possibilities that lie ahead. We will leverage our knowledge in deploying solutions for multi-site health systems to contribute to MSSS Québec's aim of significantly…
PR Newswire
27/09/2024

AMD Drugs Market to Hit USD 17.37 Billion by 2029 with 10.7% CAGR |…

Browse in-depth TOC on "Age-related Macular Degeneration (AMD) Drugs Market" Browse in-depth TOC on "Age-related Macular Degeneration (AMD) Drugs Market" 378 - Tables 54 - Figures 336 - Pages Based on molecules,the global Age-Related Macular Degeneration (AMD) drugs market has been segmented into Ranibizumab, Aflibercept, Faricimab, Pegcetacoplan, and other molecules including conbercept, brolucizumab, avacincaptad pegol, and bevacizumab-gamma among others. In 2023,...
PR Newswire
27/09/2024

Point-of-Care Diagnostics Market Surges to USD 68.8 Billion by 2030, Propelled…

Download PDF Brochure: https://www.verifiedmarketreports.com/download-sample/?rid=482155 Download PDF Brochure: https://www.verifiedmarketreports.com/download-sample/?rid=482155 Browse in-depth TOC onPoint-of-Care Diagnostics Market 202 - Pages 126 – Tables 37 – Figures Scope of The Report Global Point-of-Care Diagnostics Market Overview Market Drivers Fueling Growth in the Point-of-Care Diagnostics Market Rising Demand for Rapid Testing The increasing...
PR Newswire
27/09/2024

Press Release: Dupixent approved in the US as the first-ever biologic medicine…

Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype Following recent approvals in the EU and China, the US approval is based on two landmark phase 3 studies that showed Dupixent achieved significant reduction in exacerbations, and also showed improvements in lung function and health-related quality of life...
Nasdaq GlobeNewswire
27/09/2024

CluePoints Launches Medical & Safety Review (MSR) Software to Revolutionize…

The tool simplifies and streamlines the medical analysis of study data through user-friendly dashboards, data manipulation and cleaning, query management and full transparency over the data history. This not only improves efficiency and communication in medical oversight, but also elevates patient safety, differentiating MSR as a smarter and unique solution. The tool simplifies and streamlines the medical analysis of study data through user-friendly dashboards, data manipulation and cleaning,...
PR Newswire
27/09/2024

SciBase announces sale of Nevisense to NIH (US)

"The fact that this prestigious governmental institution has chosen to use Nevisense in their research speaks volumes about the credibility and reliability of our product," says Pia Renaudin, CEO of SciBase. "The skin barrier research market is experiencing a rapid rise in interest, and the research in this space can directly improve the lives of millions of people worldwide. We are confident that the use of our device by the NIH will lead to groundbreaking discoveries and…
PR Newswire
27/09/2024

Press Release: Dupixent approved in China as the first-ever biologic medicine…

Dupixent approved in China as the first-ever biologic medicine for patients with COPDApproval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark phase 3 studies showing Dupixent significantly reduced exacerbations, improved lung function, and also improved health-related quality of lifeCOPD is the most prevalent chronic respiratory disease in China, and is a priority within the government's Healthy China 2030 public health...
Nasdaq GlobeNewswire
27/09/2024

Sultan bin Ahmed lays foundation stone for Al Reeh Al Mursala Clinic in…

The Chairman of the Sharjah Media Council noted that the establishment of the clinic, which will feature a range of medical specializations, as well as repairs to the drinking water system in October Village, Kyrgyzstan, is part of the charitable initiatives that got underway in Aswan, Egypt, in July, which aims to help the greatest number of sick and destitute people worldwide. Sheikh Sultan bin Ahmed confirmed that the humanitarian medical campaigns would go on in other countries. The...
PR Newswire
27/09/2024

Boehringer Ingelheim partners with NCD Alliance to target Non-Communicable…

Boehringer Ingelheim has entered a partnership with the NCD Alliance, a network dedicated to shaping a world in which everyone can live a healthy and productive life, free from the preventable suffering, stigma, disability, and death caused by non-communicable diseases (NCDs). The start of the partnership was announced alongside the United Nations Global Assembly in New York.NCDs are a major global health issue. These diseases, which are not transmitted from person to person, cause 41...
Nasdaq GlobeNewswire
27/09/2024

25 Years of Innovation and Excellence: Alma Celebrates Silver Anniversary at the…

The company, which started as an energy-based device provider, quickly climbed to the top of the industry, revolutionizing treatment paradigms in various aesthetic areas and setting new benchmarks in the medical aesthetic field in terms of both clinical excellence and innovative breakthroughs. The company, which started as an energy-based device provider, quickly climbed to the top of the industry, revolutionizing treatment paradigms in various aesthetic areas and setting new benchmarks in…
PR Newswire
27/09/2024

Anbogen Announces Drug Supply Collaboration with BeiGene to Evaluate Combination…

ABT-301, a novel HDAC inhibitor, has shown promising safety and pharmacokinetic profiles in a prior Phase 1 study as a single agent. Preclinical studies indicate that ABT-301 enhances the effectiveness of anti-PD-1/anti-PD-L1 therapies by increasing CD8+ cytotoxic T cells and decreasing monocytic myeloid-derived suppressor cells within both the tumor and circulation, and inhibiting angiogenesis. These immune response enhancements may broaden the efficacy of ICIs in colorectal cancer…
PR Newswire
27/09/2024

Nexstim Receives Order for NBS System 5 in Finland

Press release, Helsinki, 27 September 2024 at 10 AM (EEST) Nexstim Receives Order for NBS System 5 in Finland Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received order from a Finnish hospital for an NBS System 5. The customer is new to Nexstim.The Nexstim Navigated Brain Stimulation (NBS) System 5 is indicated for non-invasive mapping of the primary motor cortex of the brain to its cortical gyrus. The system provides information that may be used in the assessment…
Nasdaq GlobeNewswire
27/09/2024
Altri  Comunicati